![]() |
|
|
Vol. 281, Issue 1, 93-102, 1997
Department of Anaesthesia and Pain Management, We studied healthy men who underwent blood sampling for plasma
nandrolone, testosterone and inhibin measurements before and for 32 days after a single i.m. injection of 100 mg of nandrolone ester in
arachis oil. Twenty-three men were randomized into groups receiving
nandrolone phenylpropionate (group 1, n = 7) or
nandrolone decanoate (group 2, n = 6) injected into
the gluteal muscle in 4 ml of arachis oil vehicle or nandrolone
decanoate in 1 ml of arachis oil vehicle injected into either the
gluteal (group 3, n = 5) or deltoid (group 4, n = 5) muscles. Plasma nandrolone, testosterone and
inhibin concentrations were analyzed by a mixed-effects indirect
response model. Plasma nandrolone concentrations were influenced
(P < .001) by different esters and injection sites, with higher
and earlier peaks with the phenylpropionate ester, compared with the
decanoate ester. After nandrolone decanoate injection, the highest
bioavailability and peak nandrolone levels were observed with the 1-ml
gluteal injection. Plasma testosterone concentrations were also
influenced (P < .001) by the ester and injection site, with the
most rapid, but briefest, suppression being due to the phenylpropionate
ester, whereas the most sustained suppression was achieved with the
1-ml gluteal injection. Plasma inhibin concentrations were also
significantly influenced by injection volume and site, with the lowest
nadir occurring after the nandrolone decanoate 1-ml gluteal injection.
Thus, the bioavailability and physiological effects of a nandrolone
ester in an oil vehicle are greatest when the ester is injected in a
small (1 ml vs. 4 ml) volume and into the gluteal
vs. deltoid muscle. We conclude that the side-chain
ester and the injection site and volume influence the pharmacokinetics
and pharmacodynamics of nandrolone esters in an oil vehicle in men.
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
![]() |
Y. Schrader, M. Thevis, and W. Schanzer QUANTITATIVE DETERMINATION OF METABOLIC PRODUCTS OF 19-NORANDROSTENEDIOL IN HUMAN PLASMA USING GAS CHROMATOGRAPHY/MASS SPECTROMETRY Drug Metab. Dispos., August 1, 2006; 34(8): 1328 - 1335. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Ayotte Significance of 19-norandrosterone in athletes' urine samples Br. J. Sports Med., July 1, 2006; 40(suppl_1): i25 - i29. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Bagchus, J. M. W. Smeets, H. A. M. Verheul, S. M. De Jager-Van Der Veen, A. Port, and T. B. P. Geurts Pharmacokinetic Evaluation of Three Different Intramuscular Doses of Nandrolone Decanoate: Analysis of Serum and Urine Samples in Healthy Men J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2624 - 2630. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Reznik, L. Dehennin, C. Coffin, J. Mahoudeau, and P. Leymarie Urinary Nandrolone Metabolites of Endogenous Origin in Man: A Confirmation by Output Regulation under Human Chorionic Gonadotropin Stimulation J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 146 - 150. [Abstract] [Full Text] |
||||
![]() |
D. J. Handelsman, S. Wishart, and A. J. Conway Oestradiol enhances testosterone-induced suppression of human spermatogenesis Hum. Reprod., March 1, 2000; 15(3): 672 - 679. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Anderson, S. M. Bandiera, T. K. H. Chang, and G. D. Bellward Effect of Androgen Administration During Puberty on Hepatic CYP2C11, CYP3A, and CYP2A1 Expression in Adult Female Rats Drug Metab. Dispos., October 1, 1998; 26(10): 1031 - 1038. [Abstract] [Full Text] |
||||